-0.18%
10.53%
12.04%
8.66%
62.01%
-4.97%
34.87%
AI Spotlight on LGND
Company Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression.
In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension.The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases.Further, it sells Captisol materials.
The company was incorporated in 1987 and is headquartered in Emeryville, California.
Market Data
| Last Price | 118.43 |
| Change Percentage | -0.18% |
| Open | 117.85 |
| Previous Close | 118.64 |
| Market Cap ( Millions) | 2238 |
| Volume | 15406 |
| Year High | 129.9 |
| Year Low | 67.72 |
| M A 50 | 115.07 |
| M A 200 | 100.05 |
Financial Ratios
| FCF Yield | 0.42% |
| Dividend Yield | 0.00% |
| ROE | 5.79% |
| Debt / Equity | 0.87% |
| Net Debt / EBIDTA | 441.86% |
| Price To Book | 2.59 |
| Price Earnings Ratio | 48.21 |
| Price To FCF | 240.29 |
| Price To sales | 14.68 |
| EV / EBITDA | -171.33 |
News
- Jan -13 - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
- Nov -24 - Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies
- Nov -08 - Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript
- Nov -01 - Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
- Oct -23 - Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
- Sep -06 - Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
- Aug -30 - CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030
- Aug -07 - Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript
- Jul -29 - Ligand Pharmaceuticals: Solid Performer Performing Solidly
- Jul -23 - Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
- Jul -10 - 5 Best Short-Term Stocks to Consider Investing In
- Jul -08 - Ligand to Acquire APEIRON Biologics AG for $100 Million
- Jun -27 - Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
- Jun -18 - Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
- Jun -06 - Why Is Ligand (LGND) Up 4% Since Last Earnings Report?
- Jun -06 - New Strong Buy Stocks for June 6th
- Jun -04 - Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect?
- Jun -04 - Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why
- May -23 - Ligand to Participate in Upcoming Investor Conferences
- May -20 - 3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Biopharmaceutical
Expected Growth : 13 %
What the company do ?
Ligand Pharmaceuticals' biopharmaceutical segment focuses on developing and commercializing novel therapeutics, including Captisol-enabled products and OmniAb antibody discovery platforms.
Why we expect these perspectives ?
Ligand Pharmaceuticals' 13% growth in biopharmaceuticals is driven by increasing demand for novel therapeutics, strategic partnerships, and a strong pipeline of Captisol-enabled products. Additionally, the company's expertise in antibody omics and peptide technologies, as well as its growing presence in the oncology and rare disease markets, contribute to its growth momentum.
Ligand Pharmaceuticals Incorporated Products
| Product Range | What is it ? |
|---|---|
| Captisol | A chemically modified cyclodextrin, used to improve the solubility and stability of active pharmaceutical ingredients (APIs) |
| OmniAb | A transgenic animal platform used to generate high-affinity, fully human monoclonal antibodies |
| SKY59 | A novel, orally bioavailable, small molecule inhibitor of the menin-MLL interaction |
| IAP | Inhibitor of Apoptosis Proteins (IAPs) antagonist, used to treat cancer |
| VBP | Vitamin D Binding Protein (VBP), used to treat various diseases, including cancer and autoimmune disorders |
Ligand Pharmaceuticals Incorporated's Porter Forces
Threat Of Substitutes
Ligand Pharmaceuticals Incorporated operates in a highly competitive industry, and there are several substitutes available for its products. However, the company's strong brand recognition and customer loyalty mitigate the threat of substitutes to some extent.
Bargaining Power Of Customers
Ligand Pharmaceuticals Incorporated has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often critical to its customers' operations, making it difficult for them to negotiate prices.
Bargaining Power Of Suppliers
Ligand Pharmaceuticals Incorporated relies on a few key suppliers for certain raw materials and services. While the company has some bargaining power due to its size and reputation, its suppliers also have some leverage due to the specialized nature of their products.
Threat Of New Entrants
The pharmaceutical industry has high barriers to entry, including significant regulatory hurdles and high research and development costs. This makes it difficult for new entrants to compete with established companies like Ligand Pharmaceuticals Incorporated.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, with many established companies competing for market share. Ligand Pharmaceuticals Incorporated faces intense competition from companies with similar products and technologies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.87% |
| Debt Cost | 8.55% |
| Equity Weight | 99.13% |
| Equity Cost | 8.55% |
| WACC | 8.55% |
| Leverage | 0.88% |
Ligand Pharmaceuticals Incorporated : Quality Control
Ligand Pharmaceuticals Incorporated passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PBYI | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 … |
| ARDX | Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, … |
| AMLX | Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax … |
| BYSI | BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent … |
| APLT | Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ligand Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
BeyondSpring
A-Score
1-Year Total Return ->
🥉
Applied Therapeutics
A-Score
1-Year Total Return ->
4
Puma Biotechnology
A-Score
1-Year Total Return ->
5
Amylyx Pharmaceuticals
A-Score
1-Year Total Return ->
6
